ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 1487

Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1324

Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 1570

Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study

(1554–1578) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

9:00AM-11:00AM: Abstract Number: 1173

Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease

(1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 0920

Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1285

PROMIS Symptom Clusters Predict Disease Activity in the First 6 Months in Newly Diagnosed RA Patients Starting MTX Therapy: Data from the Canadian Early Arthritis Cohort

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1161

Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models

(1155–1182) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 0864

Proteomic Analysis of Circulating Neutrophils from Osteoarthritis Patients Shows Metabolic Dysregulation That Is Associated with Decreased Physiologic Apoptosis

(0859–0885) Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1282

Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1329

R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis

(1308–1344) RA – Treatments Poster II

9:00AM-11:00AM: Abstract Number: 0909

Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0999

Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization

(0993–1012) Health Services Research Poster II

9:00AM-11:00AM: Abstract Number: 1021

Racial Disparities Between Black and White Patients in Joint Replacement Surgery: A Systematic Review

(1013–1032) Healthcare Disparities in Rheumatology Poster II: Socioeconomic Determinants

9:00AM-11:00AM: Abstract Number: 1212

Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus

(1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1481

Racial Disparities in Lupus Nephritis: A Nationwide Analysis

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].